NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a ...
NervGen Pharma (NGEN) has announced pricing of a public offering of 24M common shares, priced at $2.50 each, along with warrants to purchase the same number of shares at an exercise price of US$3.68.
Stifel Nicolaus analyst Justin Keywood reiterated a Buy rating on NervGen Pharma on May 21 and set a price target of $6.00. Memorial Day Sale – Claim 70% Off TipRanks. Unlock tr ...
NervGen Pharma Corp. NGEN stock is trading higher Tuesday morning after the clinical-stage biopharmaceutical company ...
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a ...
NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other ...
Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and ...
VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing ...
Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placebo ...
View NervGen Pharma Corp. NGEN stock quote prices, financial information, real-time forecasts, and company news from CNN.
VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results